Genmab inks $1.8B ProfoundBio buyout for would-be Elahere rival, teeing up scrap for ADC market Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24 #FierceMadness: The Best Biotech Name Tournament—Elite 8 RESULTS Oruka spins out of Paragon with 3 assets, reverse merger and cash Ascletis pulls FXR agonist from pipeline over phase 2 primary biliary cholangitis data Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak Diagonal launches with $128M and a platform slanted toward agonist antibodies Fierce Biotech Fundraising Tracker '24: Diagonal launches with $128M; T-cell therapy biotech Obsidian nets $160M | 